Holding(s) in Company

Cambridge Antibody Tech Group PLC
30 June 2006

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES



1. Name of company



CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC



2. Name of shareholder having a major interest



ASTRAZENECA UK LIMITED



3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18



ASTRAZENECA UK LIMITED       NOT DISCLOSED



4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them


15,817,983      ASTRAZENECA UK LIMITED
178,607         GREENWOOD NOMINEES LIMITED
11,962          DR PAUL NICHOLSON


32,109,070      REPRESENTING ACCEPTANCES OF THE OFFER AND RECENT
                PURCHASES TO BE REGISTERED IN THE NAME OF ASTRAZENECA UK LIMITED




5. Number of shares / amount of stock acquired



15,917,983



6. Percentage of issued class



29.92%



7. Number of shares / amount of stock disposed



N/A



8. Percentage of issued class



N/A



9. Class of security



ORDINARY 10 PENCE SHARES



10. Date of transaction



NOT DISCLOSED

11. Date company informed



29 JUNE 2006



12. Total holding following this notification



48,117,622



13. Total percentage holding of issued class following this notification



90.44%



14. Any additional information



NONE



15. Name of contact and telephone number for queries



JUSTIN HOSKINS 01223 898589



16. Name and signature of authorised company official responsible for making
this notification



JUSTIN HOSKINS, COMPANY SECRETARY



Date of notification



30 JUNE 2006



The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.




                      This information is provided by RNS
            The company news service from the London Stock Exchange